At a glance
ClinicalIndex Comparison RecordPhase 2Active· 6 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial Evaluating The Combination Of Lenvatinib Plus Pembrolizumab In Patients With Treatment Naive Metastatic Uveal Melanoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for Melanoma, Uveal. Active but no longer recruiting, targeting 6 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Uveal
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Eisai Inc.
Timeline
Phase 2Active
20232024202520262027
First PostedApr 2022
Enrollment StartAug 2022
Primary CompletionDec 2024
TodayJul 2026
Study CompletionJun 2027
First PostedApr 4, 2022
Enrollment StartAug 2, 2022
Primary CompletionDec 3, 2024
Study CompletionJun 1, 2027
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.2 years ago
Interventions
Pembrolizumabdrug
200 mg IV every 3 weeks for a maximum of 2 years.
Lenvatinibdrug
20 mg daily for a maximum of 2 years.